Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Insulin degludec - Novo Nordisk

Next Previous
Drug Profile

Insulin degludec - Novo Nordisk

Alternative Names: Insulin decludec; NN-1250; SIBA; Soluble insulin basal analogue; Tresiba

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Novo Nordisk
  • Class Antihyperglycaemics; Insulins; Pancreatic hormones
  • Mechanism of Action Ornithine decarboxylase stimulants; Phosphokinase stimulants; Protein tyrosine kinase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Type 1 diabetes mellitus; Type 2 diabetes mellitus
  • No development reported Diabetes mellitus

Most Recent Events

  • 03 Nov 2022 Health Canada approves insulin degludec injection for use in pregnant women with diabetes
  • 19 Sep 2022 3726740: No updates; NIO sponsored trial
  • 01 Mar 2022 Novo Nordisk completes a III trial in Type 2 diabetes mellitus (Combination therapy, Monotherapy, Treatment-experienced) in Portugal, USA, Germany, Japan, South Korea, Poland, Bulgaria, South Africa and Ukraine (NCT04770532)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top